ArticleMedicine2018
Central nervous system histoplasmosis: Multicenter retrospective study on clinical features, diagnostic approach and outcome of treatment.
Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list.Medical mycology · 2024Pooled it
- Treating progressive disseminated histoplasmosis in people living with HIV.The Cochrane database of systematic reviews · 2020Pooled it
- Efficacy of Cerebrospinal Fluid Beta-d-Glucan Diagnostic Testing for Fungal Meningitis: a Systematic Review.Journal of clinical microbiology · 2020Pooled it
- A Case of Neurohistoplasmosis Successfully Treated With Single High-Dose Liposomal Amphotericin B.Open forum infectious diseases · 2026Article
- Next-generation sequencing: Driving a paradigm shift from pathogen detection to systems-level analysis.Infectious medicine · 2026Article
- New 2030 Global Targets for Histoplasmosis from International Society for Human and Animal Mycology (ISHAM) 2025 Histoplasmosis Working Group.Emerging infectious diseases · 2026Article
- Hidden Histoplasmosis: Adrenal and Central Nervous System Mycosis in an Immunocompetent Patient.Cureus · 2025Article
- Practical Guidance for Clinical Microbiology Laboratories: Antibody and antigen detection methods for dimorphic fungal infections.Clinical microbiology reviews · 2025Review
- Cerebral Abscess Caused by Histoplasma capsulatum in an Immunocompetent Patient: A Case Report.Cureus · 2025Article
- Acute Myelopathy as Initial Presentation of Disseminated Histoplasmosis: A Case Report.Case reports in infectious diseases · 2025Article
- Disseminated Histoplasmosis in an Immunocompetent Patient from Southern Arizona.Journal of fungi (Basel, Switzerland) · 2024Article
- Genotypic diversity, virulence, and molecular genetic tools inMicrobiology and molecular biology reviews : MMBR · 2024Review
- Histoplasmosis in Solid Organ Transplantation.Journal of fungi (Basel, Switzerland) · 2024Review
- Central Nervous System Histoplasmosis: An Updated Insight.Pathogens (Basel, Switzerland) · 2023Article
- Review
- Headaches in a Horseback Rider.Open forum infectious diseases · 2023Article
- Intramedullary histoplasmosis of the thoracic cord as an isolated lesion: A rare case report and literature review.Surgical neurology international · 2023Article
- Article
- CNS Histoplasmosis as a Gliosarcoma mimicker: The diagnostic dilemma of solitary brain lesions.IDCases · 2022Article
- Case report: Disseminated histoplasmosis in a renal transplant recipient from a non-endemic region.Frontiers in pediatrics · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
35 authors at 20 institutions in 1 country.
Funding
Abstract
Central nervous system (CNS) involvement occurs in 5 to 10% of individuals with disseminated histoplasmosis. Most experience has been derived from small single center case series, or case report literature reviews. Therefore, a larger study of central nervous system (CNS) histoplasmosis is needed in order to guide the approach to diagnosis, and treatment.A convenience sample of 77 patients with histoplasmosis infection of the CNS was evaluated. Data was collected that focused on recognition of infection, diagnostic techniques, and outcomes of treatment.Twenty nine percent of patients were not immunosuppressed. Histoplasma antigen, or anti-Histoplasma antibodies were detected in the cerebrospinal fluid (CSF) in 75% of patients. One year survival was 75% among patients treated initially with amphotericin B, and was highest with liposomal, or deoxycholate formulations. Mortality was higher in immunocompromised patients, and patients 54 years of age, or older. Six percent of patients relapsed, all of whom had the acquired immunodeficiency syndrome (AIDS), and were poorly adherent with treatment.While CNS histoplasmosis occurred most often in immunocompromised individuals, a significant proportion of patients were previously, healthy. The diagnosis can be established by antigen, and antibody testing of the CSF, and serum, and antigen testing of the urine in most patients. Treatment with liposomal amphotericin B (AMB-L) for at least 1 month; followed by itraconazole for at least 1 year, results in survival among the majority of individuals. Patients should be followed for relapse for at least 1 year, after stopping therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.